Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.

Breast Cancer Res · 2019 · PMC6894349 · PMID 31801615

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although not significant, the combination of vistusertib plus fulvestrant showed a trend towards improved progression-free survival in the first year compared to fulvestrant as a single agent (median 7.6–8.0 versus 5.4 months).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.